Journal of Hebei Medical University ›› 2024, Vol. 45 ›› Issue (11): 1336-1341.doi: 10.3969/j.issn.1007-3205.2024.11.016

Previous Articles     Next Articles

Cost-effectiveness analysis of tenofovir in blocking mother-to-child transmission of hepatitis B

  

  1. 1.Department of Pharmacy, the Second Hospital of Nanjing City/Nanjing Affiliated Hospital of Nanjing 
    University of Traditional Chinese Medicine, Jiangsu Province, Nanjing 210003, China; 2.Department of 
    Obstetrics, the Second Hospital of Nanjing City/Nanjing Affiliated Hospital of Nanjing University of 
    Traditional Chinese Medicine, Jiangsu Province, Nanjing 210003, China; 3.Department of 
    Information, the Second Hospital of Nanjing City/Nanjing Affiliated Hospital of Nanjing 
    University of Traditional Chinese Medicine, Jiangsu Province, Nanjing 210003, China; 
    4.Department of Phase I Clinical Research Center, the Second Hospital of Nanjing 
    City/Nanjing Affiliated Hospital of Nanjing University of Traditional 
    Chinese Medicine, Jiangsu Province, Nanjing 210003, China

  • Online:2024-11-25 Published:2024-11-26

Abstract: Objective To evaluate the cost-effectiveness of domestic and imported tenofovir in blocking mother-to-child transmission of hepatitis B virus (HBV). 
Methods Pregnant patients with high HBV load who were treated and delivered at the Department of Obstetrics and Gynecology in the Second Hospital of Nanjing were enrolled in this study. A retrospective analysis was conducted to analyze clinical efficacy of domestic and imported tenofovir for mother-to-child transmission of HBV. The incremental cost-effectiveness ratio and sensitivity analysis was performed based on cost-effectiveness analysis. 
Results A total of 179 patients met the inclusion criteria, including 131 patients in the domestic group and 48 patients in the imported group. The positive-to-negative conversion rates of HBV DNA were 45.04% and 52.08% in the domestic group and the imported group respectively, while the rates of blocking mother-to-child transmission of HBV were 98.47% and 100.00% respectively, exhibiting no statistical significance (P>0.05). The total treatment costs of the domestic and imported groups were (20 313.73±11 467.36) yuan and (20 906.19±6 211.43) yuan, respectively, which did not demonstrate statistical significance (P>0.05), either. The drug expense of domestic group was observed to be significantly lower compared with its counterpart [(47.53±8.07) yuan vs. (1 118.62±200.89) yuan, P<0.05]. The incremental cost-effectiveness ratio of the domestic group and the imported group was 700.05, which was lower than the willing payment threshold of our country. This result was validated by sensitivity analysis. 
Conclusion The efficacy of domestic tenofovir is consistent with its imported counterpart on blocking mother-to-child transmission of hepatitis B, while the former has more pharmacoeconomic advantages. Consequently, it is recommended to select drugs rationally according to the practical requirements of patients in clinical practice.


Key words: hepatitis B, tenofovir, blocking mother-to-child transmission